MedPath

Sucampo Pharma Americas, LLC

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
-
Employees
-
Market Cap
-
Website

Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo

Phase 3
Completed
Conditions
Chronic Idiopathic Constipation
Interventions
Drug: Placebo
Drug: Lubiprostone
First Posted Date
2017-03-31
Last Posted Date
2020-01-14
Lead Sponsor
Sucampo Pharma Americas, LLC
Target Recruit Count
552
Registration Number
NCT03097861
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Investigative Site, Richmond, Virginia, United States

๐Ÿ‡บ๐Ÿ‡ธ

Investigative Sitee, High Point, North Carolina, United States

๐Ÿ‡บ๐Ÿ‡ธ

Investigative Site 2, Jackson, Tennessee, United States

Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy Volunteers

Phase 3
Completed
Conditions
Healthy Volunteers
First Posted Date
2017-01-05
Last Posted Date
2020-03-09
Lead Sponsor
Sucampo Pharma Americas, LLC
Target Recruit Count
49
Registration Number
NCT03010631
Locations
๐Ÿ‡บ๐Ÿ‡ธ

ICON, San Antonio, Texas, United States

Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged โ‰ฅ 6 Years to < 18 Years With Functional Constipation

Phase 3
Completed
Conditions
Constipation - Functional
Interventions
First Posted Date
2016-05-10
Last Posted Date
2020-05-15
Lead Sponsor
Sucampo Pharma Americas, LLC
Target Recruit Count
87
Registration Number
NCT02766777
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Northwest Arkansas Pediatric Clinic, Fayetteville, Arkansas, United States

๐Ÿ‡บ๐Ÿ‡ธ

Pioneer Clinical Research, Bellevue, Nebraska, United States

๐Ÿ‡บ๐Ÿ‡ธ

Methodist Medical Center, Peoria, Illinois, United States

and more 10 locations

Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome

Phase 2
Terminated
Conditions
Irritable Bowel Syndrome
Interventions
Drug: Placebo
Drug: Lubiprostone
First Posted Date
2015-09-09
Last Posted Date
2019-12-27
Lead Sponsor
Sucampo Pharma Americas, LLC
Target Recruit Count
71
Registration Number
NCT02544152
Locations
๐Ÿ‡บ๐Ÿ‡ธ

E Squared Research, Inc., Huntsville, Alabama, United States

๐Ÿ‡บ๐Ÿ‡ธ

Inland Empire Liver Foundation, Rialto, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Wake Research Associates, LLC, Raleigh, North Carolina, United States

and more 12 locations

Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy

Phase 2
Terminated
Conditions
Oral Mucositis
Interventions
Drug: Placebo
Drug: Cobiprostone
Drug: Standard Care - Chemotherapy
Radiation: Standard Care - Radiation
First Posted Date
2015-09-04
Last Posted Date
2019-12-02
Lead Sponsor
Sucampo Pharma Americas, LLC
Target Recruit Count
47
Registration Number
NCT02542215
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Investigational Site, Madison, Wisconsin, United States

Lubiprostone for Children With Constipation

Phase 3
Completed
Conditions
Constipation - Functional
Interventions
First Posted Date
2014-05-14
Last Posted Date
2020-01-21
Lead Sponsor
Sucampo Pharma Americas, LLC
Target Recruit Count
419
Registration Number
NCT02138136
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Gastrointestinal Associates, PA, Jackson, Mississippi, United States

๐Ÿ‡บ๐Ÿ‡ธ

Children's Hospital of Pittsburgh UPMC, Pittsburgh, Pennsylvania, United States

๐Ÿ‡บ๐Ÿ‡ธ

Baylor College of Medicine, Houston, Texas, United States

and more 82 locations

Lubiprostone in Children With Functional Constipation

Phase 3
Completed
Conditions
Constipation - Functional
Interventions
Drug: Lubiprostone
Drug: Placebo
First Posted Date
2014-01-22
Last Posted Date
2020-07-21
Lead Sponsor
Sucampo Pharma Americas, LLC
Target Recruit Count
606
Registration Number
NCT02042183
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Loma Linda University Health Care, Loma Linda, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

๐Ÿ‡บ๐Ÿ‡ธ

Baylor College of Medicine, Houston, Texas, United States

and more 113 locations

A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration

Phase 2
Completed
Conditions
Dry Age-related Macular Degeneration
Interventions
First Posted Date
2011-06-23
Last Posted Date
2019-12-10
Lead Sponsor
Sucampo Pharma Americas, LLC
Target Recruit Count
33
Registration Number
NCT01379560
Locations
๐Ÿ‡ฆ๐Ÿ‡น

Medical University of Vienna, Vienna, Austria

Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)

Phase 3
Completed
Conditions
Opioid-induced Bowel Dysfunction
Interventions
Drug: Placebo
Drug: Lubiprostone
First Posted Date
2011-02-17
Last Posted Date
2020-02-11
Lead Sponsor
Sucampo Pharma Americas, LLC
Target Recruit Count
439
Registration Number
NCT01298219
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Hartwell Research Group, Anderson, South Carolina, United States

๐Ÿ‡บ๐Ÿ‡ธ

North Alabama Research Center, Athens, Alabama, United States

๐Ÿ‡บ๐Ÿ‡ธ

Sunstone Medical Research, Medford, Oregon, United States

and more 137 locations

Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension

Phase 2
Terminated
Conditions
Portal Hypertension
Interventions
Drug: Placebo
Drug: Cobiprostone
First Posted Date
2008-08-19
Last Posted Date
2019-11-18
Lead Sponsor
Sucampo Pharma Americas, LLC
Target Recruit Count
9
Registration Number
NCT00737594
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of Texas Southwestern Medical Center, Dallas, Texas, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath